H.C. Wainwright raised the firm’s price target on Pyxis Oncology (PYXS) to $7 from $5 and keeps a Buy rating on the shares after the company provided a clinical data update on studies evaluating Micvo as a therapy for relapsed/metastatic head and neck squamous cell carcinoma. The firm says the “consistent” efficacy and “manageable” safety profile increase its confidence in the second-line setting.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PYXS: